Sepsis is a medical emergency.
Every minute counts!
We are pioneering technology that analyzes the patient's immune system to rapidly detect sepsis.
Immunexpress' technology is leading a paradigm shift in sepsis diagnosis — it uses blood gene expression to quantify the patient's immune response to a pathogen, rather than the traditional approach which tries to find a causative pathogen.
Our mission is to develop diagnostic technologies to help clinicians and patients to fight this life-threatening disease.
Sepsis is caused by a patient’s overwhelming immune response to an infection and, if undetected or left untreated,
leads to tissue damage, organ failure, permanent disability and often death.
Around the world physicians struggle to rapidly and reliably identify sepsis due to the lack of adequate diagnostic tools.
Traditional tests produce clinically actionable results in 24-48 hours for 20% of all patients tested.
SeptiCyte® RAPID produces clinically actionable results in one hour for 100% of patients tested.
SeptiCyte® RAPID is highlighted in this 10News First Brisbane interview.
Accurate diagnosis of sepsis is time-critical to save lives.
We have developed the fully automated SeptiCyte® RAPID cartridge, compatible with the Biocartis Idylla™ platform, enabling the quantification and analysis of gene expression from whole blood to diagnose sepsis in suspected patients. With this technology, we aim to improve clinical and economic outcomes for patients and to benefit all key healthcare stakeholders: medical professionals and payers.